fda compounding semaglutide enforcement october 2025 news Compounded Semaglutide: Legal & Safe FDA Warns Companies Over Compounded

TRIUMPH-4 data suggests retatrutide delivers on both fronts, though a dedicated cardiovascular outcomes trial running through 2027-2028 will provide definitive proof

She has more than 300 publications, is an frequent speaker on obesity and diabetes treatments and remains an active consultant and advisor to companies developing drugs, devices, lifestyle programs and medical approaches to obesity management.

The magnitude of weight loss was dose-dependent, with the 2.4 mg dose showing a clinically meaningful reduction

CMS may grant an ECE to one or more ASCs that have not requested an ECE if CMS determines that (i) A systemic problem with a CMS data collection system directly impacted the ability of the ASC to comply with a quality data reporting requirement

J.JarrettM

This is a companion supplement for people already on prescription GLP-1 medications